Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy

Human Gene Therapy

Volumn 9, Issue 7, 1998, Pages 989-995

  Lemay, D R ^a   Kittaka, M ^a   Gordon, E M ^a   Gray, B ^a   Stins, M F ^a   Mccomb, J G ^a   Jovanovic, S ^a   Tabrizi, P ^a   Weiss, M H ^a   Bartus, R ^b   Anderson, W F ^a   Zlokovic, B V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALKERMES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ DERIVATIVE; GANCICLOVIR; LOBRADIMIL; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CYTOTOXICITY; GENE THERAPY; GLIOMA CELL; HERPES SIMPLEX VIRUS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RAT; SUICIDE GENE;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 17344365603     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.7-989     Document Type: Article

References (9)

1. BARTUS, M.R., SNODGRASS, P.A., and BLUNT, D.G. (1996). Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp. Neurol. 142, 14-28.
2. BARTUS, R.T., ELLIOTT, R., HAYWARD, N., DEAN, R., MCEWEN, E.L., and FISHER, S.K. (1996). Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: Evidence for a sensitive, autoregulated, receptor-mediated system. Immunopharmacology 33, 270-278.
3. BOVIATSIS, E.J., PARK, J.S., SENA-ESTEVES, M., KRAMM, C.M., CHASE, M., EFIRD, J.T., WEI, M.X., BREAKEFIELD, X.O., and CHIOCCA, E.A. (1994). Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54, 5745-5751.
4. CHEN, C.H., CHANG, Y.N., RYAN, P., LINSCOTT, M., MCGARRITY, G.J., and CHIANG, Y.L. (1995). Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect." Hum. Gene Ther. 6, 1467-1476.
5. CHEN, S.H., SHINE, H.D., GOODMAN, J.C., GROSSMAN, R.F., and WOO, S.L.C. (1994). Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. U.S.A. 91, 3054-3057.
6. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vectorproduced cells for treatment of experimental brain tumors. Science 256, 1550-1552.
7. DAVEY, P.G. (1990). New drugs: New antiviral and antifungal drugs. Br. Med. J. 300, 793-798.
8. ZLOKOVIC, B.V., and APUZZO, M. (1997a). Cellular and molecular neurosurgery: Pathways from concept to reality. I. Target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery 40(4), 789-804.
9. ZLOKOVIC, B.V., and APUZZO, M. (1997b). Cellular and molecular neurosurgery: Pathways from concept to reality. II. Vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery 40(4), 805-813.